Evidence map›Paper›PMID 40158167›Full record

ArticleCardiovascular diabetology2025

Joint association of estimated glucose disposal rate and systemic inflammation response index with mortality in cardiovascular-kidney-metabolic syndrome stage 0-3: a nationwide prospective cohort study.

Yuwen Chen, Wenbin Lian, Lunzhe Wu, An'an Huang, Deliang Zhang, Bingchen Liu, Yuangang Qiu, Qucheng Wei

Abstract read
In one paragraph

Article in Cardiovascular diabetology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Observational
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yuwen Chen *Department of Cardiology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310009, China.
Wenbin Lian *The First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, 310009, China.
Lunzhe WuDepartment of Cardiology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310009, China.
An'an HuangDepartment of Cardiology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310009, China.
Deliang ZhangDepartment of Cardiology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310009, China.
Bingchen LiuDepartment of Cardiology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310009, China. liubingchen111@zju.edu.cn.
Yuangang QiuDepartment of Cardiology, First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, 310009, China. 13957120120@163.com.
Qucheng WeiDepartment of Cardiology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310009, China. wqc2060@zju.edu.cn.

Funding

Key Research and Development Program of Zhejiang Province 2025C02144
6 · The paper itself

Abstract

backgroundThe Cardiovascular-Kidney-Metabolic (CKM) syndrome underscores the complex interactions among metabolic disorders, kidney disease, and cardiovascular conditions. Insulin resistance (IR) and inflammation are crucial in CKM syndrome development, but their combined effect in stages 0-3 remains unclear.

methodsUsing data from the National Health and Nutrition Examination Survey (NHANES), we included 18,295 participants with CKM syndrome stages 0-3 from 10 cycles between 1999 and 2018. IR was assessed using the estimated glucose disposal rate (eGDR), and systemic inflammation was evaluated using the Systemic Inflammation Response Index (SIRI). The primary endpoint was all-cause mortality, and the secondary endpoint was cardiovascular disease (CVD) mortality.

resultsOver an average follow-up period of 121 months, we recorded 1,998 all-cause deaths and 539 CVD deaths. Both eGDR and SIRI were independent risk factors for mortality. The hazard ratios (HR) for eGDR were 0.90 (0.86, 0.94) for all-cause mortality and 0.85 (0.78, 0.93) for CVD mortality, per unit increase in eGDR. For SIRI, the HRs were 1.16 (1.11, 1.21) for all-cause mortality and 1.33 (1.19, 1.46) for CVD mortality, per unit increase in SIRI. Compared to individuals with high eGDR and low SIRI levels, those with low eGDR and high SIRI levels exhibited significantly higher mortality risks, with HRs of 1.97 (1.58, 2.44) for all-cause mortality and 2.35 (1.48, 3.73) for CVD mortality. Subgroup analysis revealed that the combined impact of eGDR and SIRI was particularly significant in patients under 60 years old.

conclusionIn CKM syndrome stages 0-3, eGDR and SIRI have joint effect on mortality. Combining these markers can help identify high-risk individuals early, enabling timely monitoring and intervention to improve outcomes.

Indexed as

Blood GlucoseCardio-Renal SyndromeCardiovascular DiseasesInflammationInflammation MediatorsInsulin ResistanceMetabolic SyndromeAdultAgedBiomarkersCause of DeathFemaleHumansMaleMiddle AgedNutrition SurveysBiomarkersBlood GlucoseInflammation MediatorsCardiovascular-kidney-metabolic syndromeEstimated glucose disposal rateMortalityNational health and nutrition examination surveySystemic inflammation response index

Identifiers

PMID40158167
PMCPMC11955130

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.